Evidence map›Paper›PMID 12515313›Full record

ArticleNeurochemical research2002

Activation of phospholipases A2 and D of a human neuroblastoma cell line (LA-N-2) by N-dodecyl-L-lysine amide (compound 24), a putative G protein activator: characteristics of inhibition by (-)-nicotine.

Byron M Garnham, Shirley Fitzpatrick-Wong, Walter Schunack, Bernd Nürnberg, Giuseppe Sorrentino, Fiona E Parkinson, Julian N Kanfer, Daniel S Sitar

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Byron M GarnhamDepartment of Pharmacology and Therapeutics, University of Manitoba, A220-770 Bannatyne Avenue, Winnipeg, MB, Canada R3E 0W3.
Shirley Fitzpatrick-Wong
Walter Schunack
Bernd Nürnberg
Giuseppe Sorrentino
Fiona E Parkinson
Julian N Kanfer
Daniel S Sitar
University of Manitoba · CAFreie Universität Berlin · DEHeinrich Heine University Düsseldorf · DEParthenope University of Naples · ITUniversity of Naples Federico II · IT

Funding

CIHR 15297
6 · The paper itself

Abstract

Compound 24, an alkyl-substituted amino acid amide, previously found to activate pertussis toxin-sensitive G proteins in cell membranes and membrane protein fractions, was used as a tool to determine the mechanism/location of nicotine inhibition of amyloid beta peptide-stimulated phospholipase A2 and D activities in a human neuroblastoma cell line, LA-N-2, in vitro. In contrast to our previous findings with amyloid beta peptide, these phospholipase activations by compound 24 were not inhibited by (-)-nicotine, cholera toxin or tetanus toxin pretreatment. The contrasting activation of these phospholipases by amyloid beta peptide and compound 24 are discussed.

Indexed as

Base SequenceDNA PrimersEnzyme ActivationEnzyme InhibitorsGTP-Binding ProteinsHumansLysineNeuroblastomaNicotinePhospholipase DPhospholipases APhospholipases A2Receptors, NicotinicTumor Cells, CulturedDNA PrimersEnzyme InhibitorsGTP-Binding ProteinsLysineN-dodecyl-L-lysine amideNicotinePhospholipase DPhospholipases APhospholipases A2Receptors, Nicotinic

Identifiers

PMID12515313
OpenAlexW219300997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.